Daily adjustment of radiation dose in MRI-guided SBRT for abdominal and pelvic tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses MR-guided stereotactic body radiotherapy with adaptive fractionation to adjust both target coverage and dose per fraction in real time. The goal is to reduce geographic miss and minimize dose to nearby organs at risk by adapting the plan online across the five treatment fractions. Eligible patients have abdominal or pelvic tumors, good performance status, and tumors within reach of MRI-guided SBRT with dilated constraints to dose-limiting OARs. Treatments are delivered over five fractions, with careful monitoring of organ motion and anatomy to tailor the dose per fraction when needed. The study is sponsored by the University of Zurich and conducted at University Hospital Zurich.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Karnofsky performance status ≥70
* Abdominal or pelvic malignancy (primary or secondary) with previous histological confirmation of the primary tumour, amenable to SBRT in 5 fractions (excluding SBRT to primary tumour in patients with prostate cancer) Note: patients with primary prostate cancer are eligible, but SBRT to the primary tumour in the prostate cannot be performed within the study
* Total prescribed SBRT dose \> 30 Gy (constraint for dose-limiting OAR) over 5 treatment fractions
* Distance of the GTV ≤ 1 cm from at least one dose-limiting OAR (bowel / duodenum / stomach) in the available diagnostic images
* Patients able to tolerate long (approximately 60 minutes) treatment time according to clinical evaluation of the treating radiation oncologist
* Patients willing and able to comply with scheduled visits, treatment, and other trial procedures

Exclusion Criteria:

* Previous radiation therapy directly overlapping with planned SBRT (type I re-irradiation)
* More than one PTV irradiated in the same plan
* Contraindications for MRI, e.g., patients with metal fragments or implanted devices that are not MR compatible such as certain types of pacemakers and aneurysm clips or severe claustrophobia
* SBRT not indicated or not possible
* Inability to follow the procedures of the trial, e.g. due to language problems of the participant

Where it's running

• University Hospital Zurich
  Zurich, Canton of Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Reinhardt Krcek, Dr. med. — University of Zurich
• Study coordinator: Jan Unkelbach, Prof. Dr. rer. nat.
• Email: jan.unkelbach@usz.ch
• Phone: +41 44 255 85 49

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using 3D models to improve surgery for children's pelvic and retroperitoneal tumors

  This study is testing if using 3D models of tumors can help doctors plan surgeries better for children with pelvic and retroperitoneal tumors compared to regular 2D images.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, Île-de-France Region · NCT06418243

• Registry for Online Adaptive Radiotherapy in Pelvic and Thoracic Tumors

  This study is testing if a new type of radiotherapy that adapts to patients' changing needs can reduce side effects and improve outcomes for people with pelvic or thoracic tumors compared to standard treatment.

  Recruiting University Medical Center Goettingen · Göttingen · NCT06185062

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.